卵管がん(Fallopian Tube Cancer):治療薬開発パイプライン動向(2015年上半期版)...市場調査レポートについてご紹介

【英文タイトル】Fallopian Tube Cancer - Pipeline Review, H1 2015

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 7
Introduction 9
Global Markets Direct Report Coverage 9
Fallopian Tube Cancer Overview 10
Therapeutics Development 11
Pipeline Products for Fallopian Tube Cancer – Overview 11
Pipeline Products for Fallopian Tube Cancer – Comparative Analysis 12
Fallopian Tube Cancer – Therapeutics under Development by Companies 13
Fallopian Tube Cancer – Therapeutics under Investigation by Universities/Institutes 18
Fallopian Tube Cancer – Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Fallopian Tube Cancer – Products under Development by Companies 22
Fallopian Tube Cancer – Products under Investigation by Universities/Institutes 27
Fallopian Tube Cancer – Companies Involved in Therapeutics Development 28
AbbVie Inc. 28
Acceleron Pharma, Inc. 29
Adaptimmune Limited 30
Amgen Inc. 31
Array BioPharma Inc. 32
Astex Pharmaceuticals, Inc. 33
AstraZeneca PLC 34
Bayer AG 35
BioMarin Pharmaceutical Inc. 36
Bionomics Limited 37
Boehringer Ingelheim GmbH 38
Celldex Therapeutics, Inc. 39
Celsion Corporation 40
Cerulean Pharma, Inc. 41
Clovis Oncology, Inc. 42
Corcept Therapeutics Incorporated 43
CTI BioPharma Corp. 44
Curis, Inc. 45
Eli Lilly and Company 46
Exelixis, Inc. 47
F. Hoffmann-La Roche Ltd. 48
Galena Biopharma, Inc. 49
Genentech, Inc. 50
GlaxoSmithKline plc 51
Glycotope GmbH 52
Gradalis Inc. 53
ImmunoGen, Inc. 54
Immunotope, Inc. 55
Immunovaccine, Inc. 56
Johnson & Johnson 57
Karyopharm Therapeutics, Inc. 58
Lee’s Pharmaceutical Holdings Limited 59
MabVax Therapeutics Holdings, Inc. 60
MedImmune, LLC 61
Merck & Co., Inc. 62
Merrimack Pharmaceuticals, Inc. 63
Millennium Pharmaceuticals, Inc. 64
NeoStem, Inc. 65
Novartis AG 66
Oasmia Pharmaceutical AB 67
OBI Pharma, Inc. 68
Oncolytics Biotech Inc. 69
OncoMed Pharmaceuticals, Inc. 70
Onxeo SA 71
Oxford BioMedica plc 72
OXiGENE, Inc. 73
Pharma Mar, S.A. 74
Pharmacyclics, Inc. 75
PsiOxus Therapeutics, Ltd. 76
Recepta Biopharma S.A. 77
Sanofi Pasteur SA 78
Sotio a.s. 79
Synta Pharmaceuticals Corp. 80
TapImmune Inc. 81
Tesaro, Inc. 82
TetraLogic Pharmaceuticals 83
TRACON Pharmaceuticals, Inc. 84
VentiRx Pharmaceuticals, Inc. 85
Fallopian Tube Cancer – Therapeutics Assessment 86
Assessment by Monotherapy Products 86
Assessment by Target 87
Assessment by Mechanism of Action 91
Assessment by Route of Administration 94
Assessment by Molecule Type 96
Drug Profiles 98
abexinostat hydrochloride – Drug Profile 98
abiraterone acetate – Drug Profile 100
ABT-767 – Drug Profile 103
alisertib – Drug Profile 104
anetumab ravtansine – Drug Profile 108
AZD-1775 – Drug Profile 110
AZD-2014 – Drug Profile 112
AZD-5363 – Drug Profile 114
belinostat – Drug Profile 116
bevacizumab – Drug Profile 119
binimetinib – Drug Profile 124
birinapant – Drug Profile 128
BNC-105P – Drug Profile 131
cabozantinib s-malate – Drug Profile 133
Cancer Stem Cell Therapy – Drug Profile 136
CDX-1401 – Drug Profile 137
Cell Therapy to Target NY-ESO-1 and LAGE-1 for Oncology – Drug Profile 139
Cell Therapy to Target WT1 for Cancer – Drug Profile 141
CRLX-101 – Drug Profile 142
CUDC-427 – Drug Profile 144
dalantercept – Drug Profile 145
DCVAC/OvCa – Drug Profile 147
demcizumab – Drug Profile 148
Dendritic Cell Therapy for Ovarian, Peritoneal and Fallopian Tube Cancer – Drug Profile 152
DMUC-4064A – Drug Profile 153
DPX-Survivac – Drug Profile 154
EGEN-001 – Drug Profile 157
elesclomol – Drug Profile 159
enadenotucirev – Drug Profile 161
erismodegib – Drug Profile 163
fosbretabulin tromethamine – Drug Profile 166
GALE-301 – Drug Profile 170
ganetespib – Drug Profile 172
gimatecan – Drug Profile 176
guadecitabine – Drug Profile 178
IMGN-853 – Drug Profile 181
IMT-1012 – Drug Profile 182
ipafricept – Drug Profile 183
LCL-161 – Drug Profile 185
lifastuzumab vedotin – Drug Profile 187
LY-2606368 – Drug Profile 189
mifepristone – Drug Profile 190
MK-2206 – Drug Profile 193
motolimod – Drug Profile 196
nintedanib – Drug Profile 198
niraparib – Drug Profile 202
NSC-748933 – Drug Profile 204
OBI-822/821 – Drug Profile 205
olaratumab – Drug Profile 207
paclitaxel – Drug Profile 209
paclitaxel poliglumex – Drug Profile 211
PankoMab-GEX – Drug Profile 215
pazopanib hydrochloride – Drug Profile 216
pelareorep – Drug Profile 221
ralimetinib mesylate – Drug Profile 226
ramucirumab – Drug Profile 227
RebmAb-100 – Drug Profile 232
regorafenib – Drug Profile 234
rucaparib phosphate – Drug Profile 237
selinexor – Drug Profile 240
seribantumab – Drug Profile 244
SG-2000 – Drug Profile 247
talazoparib – Drug Profile 249
TPIV-200 – Drug Profile 252
trabectedin – Drug Profile 254
TRC-105 – Drug Profile 258
trebananib – Drug Profile 260
TroVax – Drug Profile 263
Vaccine for cancer – Drug Profile 266
Vaccine for Oncology – Drug Profile 268
varlilumab – Drug Profile 269
vCP-2292 – Drug Profile 271
X-82 – Drug Profile 273
Fallopian Tube Cancer – Recent Pipeline Updates 275
Fallopian Tube Cancer – Dormant Projects 417
Fallopian Tube Cancer – Discontinued Products 419
Fallopian Tube Cancer – Product Development Milestones 420
Featured News & Press Releases 420
Appendix 426
Methodology 426
Coverage 426
Secondary Research 426
Primary Research 426
Expert Panel Validation 426
Contact Us 426
Disclaimer 427


【レポート販売概要】

■ タイトル:卵管がん(Fallopian Tube Cancer):治療薬開発パイプライン動向(2015年上半期版)
■ 英文:Fallopian Tube Cancer - Pipeline Review, H1 2015
■ 発行日:2015年3月19日
■ 調査会社:Global Markets Direct
■ 商品コード:GMDHC6248IDB
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。